Seattle, WA -- (SBWire) -- 09/25/2019 --Global Sucralfate Market, by Formulation (Tablet and Liquid), by Indication (Gastric Ulcers, Duodenal Ulcers, Gastro Esophageal Reflux Disease (GERD), and Other Indications), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2018 – 2026

Sucralfate is a medication that is used for the treatment of gastroesophageal infection, stomach ulcers, stomach inflammation, and radiation proctitis. It is the generic form of brand-name drug 'Carafate'. Sucralfate is a hydroxy aluminum salt if sucrose octasulfate that functions as local mucosal adherent. It creates a layer of coating over ulcers by sticking to the affected area, so that it protects the affected area from internal acids and enzymes and helps the ulcer to heal faster.

Sucralfate is also indicated for the treatment of ulcers in cats, horses, dogs that are caused due to liver disease, toxic chemical ingestion, drugs (particularly non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids), inflammatory bowel disease, renal failure, stress (trauma, shock, sepsis, and burns), and carcinoma.

Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2325

Increasing number of research and development to innovate novel medicines using sucralfate is expected to drive growth of the global sucralfate market. For instance, in April 2018, American Broncho Esophagological Association report, used sucralfate with hone aides for the treatment of esophageal injury in children and infants. Such injuries in children are related to button batteries (BB) and small disc shaped batteries that are commonly found in toys. When sucralfate is used with honey it offers symptomatic relief to esophageal injury and helps to mitigate button batteries.

Shortage of drugs around the world is expected to hamper growth of the global sucralfate market. For instance, according to Drug Shortages Canada, report of September 2018, APO-SUCRALFATE - TAB 1G (APOTEX INC) that contained sucralfate was not available due to disruption in the manufacturing of the drug. The drug is used for the treatment of peptic ulcer and gastro esophageal reflux disease (GERD).

North America is expected to hold dominant position in the sucralfate market, owing to increasing number of clinical studies. For instance, University of Texas is conducting a clinical phase II study on sucralfate to improve oral intake in children with infectious oral ulcers. The study is expected to be completed by June 2019.

By 2026, Asia Pacific is expected to witness significant growth in the global sucralfate market due to increasing prevalence of H. pylori associated peptic ulcer disease, gastric cancer, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.

Key players operating in the global sucralfate market include, SRL Pharma, Nitika Chemicals., Teva Pharmaceutical Industries Ltd., Lisapharma S.p.A, Aptalis Pharma US, Inc., Uniprix Group, Rx Outreach, Abcam Plc, and Quimica Alkano.

Get PDF Brochure of Research Report - https://www.coherentmarketinsights.com/insight/request-pdf/2325

Sucralfate Market – Taxonomy

By Formulation

Tablet

Liquid

By Indication

Gastric Ulcers

Duodenal Ulcers

Gastro Esophageal Reflux Disease (GERD)

Other Indications

By Region

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

To view the original version on The Express Wire visit https://www.coherentmarketinsights.com/ongoing-insight/sucralfate-market-2325

About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.